The company said its Q3 2024 revenue rose to $684.0 million from $670.7 million a year earlier, an increase of $13.3 million (about 2%). Its Diagnostics segment grew $20.2 million (6%), while the Life Sciences segment fell $6.9 million (2%).

1. 01

   The company said its Q3 2024 revenue rose to $684.0 million from $670.7 million a year earlier, an increase of $13.3 million (about 2%). Its Diagnostics segment grew $20.2 million (6%), while the Life Sciences segment fell $6.9 million (2%).

2. 02

   Revvity said its gross margin for Q3 2024 was 56.3%, up 72 basis points from 55.5% a year earlier, and its operating margin rose from 10% to 14%. The company cited higher sales volume, productivity gains and cost containment as the factors.

3. 03

   The company said its operating cash flow from continuing operations for the 9 months ended September 29, 2024 was $489.5 million, up $430.7 million from $58.8 million a year earlier. It cited higher continuing operations earnings and lower cash used for working capital investment as the factors.

4. 04

   The company said on October 24, 2024 that it terminated its existing share repurchase program and approved a new program of up to $1.0 billion. In Q3 2024, it also fully repaid its 0.850% Senior Unsecured Notes, totaling $711.5 million, which had matured.

Key figures

Quarter ended September 29, 2024

Revenue

$684M

Operating income

$98M

Net income

$94M

EPS

$0.77

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.